The epidemiology and societal costs of myasthenia gravis in Norway: A non‐interventional study using national registry data
European Journal of Neurology · 2024
DOI: 10.1111/ene.16233 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Ingrid Engebretsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oslo Economics, Oslo, Norway. Hauptthemen laut MEDLINE: Health Care Costs, Myasthenia Gravis. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Background and purpose With the emergence of new treatment options for myasthenia gravis (MG), there is a need for information regarding epidemiology, healthcare utilization, and societal costs to support economic evaluation and identify eligible patients. We aimed to enhance the understanding of these factors using nationwide systematic registry data in Norway.
Methods
We received comprehensive national registry data from five Norwegian health‐ and work‐related registries. The annual incidence and prevalence were estimated for the period 2013–2021 using nationwide hospital and prescription data. The direct, indirect (productivity losses) and intangible costs (value of lost life‐years [LLY] and health‐related quality of life [HRQoL]) related to MG were estimated over a period of 1 year.
Results
In 2021, the incidence of MG ranged from 15 to 16 cases per year per million population depending on the registry used, while the prevalence varied between 208.9 and 210.3 per million population. The total annual societal costs of MG amounted to EUR 24,743 per patient, of which EUR 3592 (14.5%) were direct costs, EUR 8666 (35.0%) were productivity loss, and EUR 12,485 (50.5%) were lost value from LLY and reduced HRQoL.
Conclusion
The incidence and prevalence of MG are higher than previously estimated, and the total societal costs of MG are substantial. Our findings demonstrate that productivity losses, and the value of LLY and HRQoL constitute a considerable proportion of the total societal costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oslo Economics, Oslo, Norway.
- Department of Clinical Medicine, University of Bergen, Bergen, Norway.
- Department of Neurology, Haukeland University Hospital, Bergen, Norway.
- Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway.
- Department of Public Health, Research Unit for General Practice, University of Southern Denmark, Odense M, Denmark.
- UCB Pharma AB, Stockholm, Sweden.
ORCID-Profile: Ingrid Engebretsen, Ingrid Lindberg-Schager, Christoffer Bugge
Förderung
- UCB Pharma
Zitieren
APA
Engebretsen, I., Gilhus, N. E., Kristiansen, I. S., Sæther, E. M., Lindberg-Schager, I., Arneberg, F., & Bugge, C. (2024). The epidemiology and societal costs of myasthenia gravis in Norway: A non‐interventional study using national registry data. European Journal of Neurology. https://doi.org/10.1111/ene.16233
Vancouver
Engebretsen I, Gilhus NE, Kristiansen IS, Sæther EM, Lindberg-Schager I, Arneberg F, et al. The epidemiology and societal costs of myasthenia gravis in Norway: A non‐interventional study using national registry data. European Journal of Neurology. 2024. doi:10.1111/ene.16233
BibTeX
@article{Engebretsen2024,
author = {Engebretsen, Ingrid and Gilhus, Nils Erik and Kristiansen, Ivar Sønbø and Sæther, Erik Magnus and Lindberg-Schager, Ingrid and Arneberg, Fredrik and Bugge, Christoffer},
title = {The epidemiology and societal costs of myasthenia gravis in Norway: A non‐interventional study using national registry data},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16233}
}
EUVIMED